OrganaBio Acquires Excellos to Expand Cell Therapy CDMO Services

OrganaBio, LLC, a manufacturer of GMP cells and blood products and provider of cell isolation and cryopreservation services, has acquired substantially all of the operating assets of San Diego-based Excellos Inc. to create a bicoastal cell therapy contract development and manufacturing organization. Newly formed OrganaBio subsidiary Excellos Labs, LLC (“Excellos Labs”) will be responsible for San Diego operations going forward. The acquisition creates a more comprehensive cell therapy service provider, combining complementary capabilities in addition to expanding geographic coverage.

OrganaBio will continue to support developers working with both organizations, improving timely access to critical starting materials and manufacturing redundancy within a single relationship.

The new OrganaBio is positioned to address a structural challenge for cell therapy developers and organizations requiring PBMC isolation and cryopreservation services. Dependency on a single source for PBMC isolation and cryopreservation services creates risk in supply chains, while splitting volume across multiple vendors introduces quality risks such as lot-to-lot variability and inconsistent process execution across sites. OrganaBio now offers bicoastal cGMP manufacturing, PBMC isolation for clinical trial samples, and cryopreservation of patient leukopaks ahead of manufacturing, all operating under a single quality framework. This means the company can now deliver the geographic and infrastructure redundancy customers need without the trade-offs that typically come with it, shortening the path from cell therapy development to patients waiting for these treatments.